Recordati has signed an exclusive license agreement with Pharmaplan for the marketing and sales of silodosin in South Africa. Silodosin is a new compound indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Reportedly, Pharmaplan will be responsible for filing with the NDA, requesting marketing approval in South Africa.
Giovanni, chairman and CEO of Recordati, said: “We are delighted with this new agreement with Pharmaplan in South Africa, a market in which our partner already successfully markets three important products.”
Recordati is a European specialty pharmaceutical group, engaged in the research, development, manufacturing and marketing of pharmaceuticals products.